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Background: The cytotoxic T lymphocyte-
associated antigen 4 gene (CTLA-4) encode the
T cell receptor involved in the control of T cell
proliferation and mediates T cell apoptosis.
The receptor protein is a specific T lymphocyte
surface antigen that is detected on cells only
after antigen presentation. Thus, CTLA-4 is
directly involved in both immune and autoim-
mune responses and may be involved in the
pathogenesis of multiple T cell-mediated
autoimmune disorders. There is polymorphism
at position 49 in exon 1 of the CTLA-4 gene,
providing an A-G exchange. Moreover, we
assessed the CTLA-4 49 (Thr/Ala) polymor-
phism in diabetic patients and first-degree rela-
tives as compared to control subjects. 
Research design and methods: Three loci
(HLA-DQB1, DQA1 and CTLA-4) were
analysed in 62 type 1 diabetic patients, 72 first-
degree relatives and 84 nondiabetic control
subjects by means of PCR-RFLP.
Results: A significant enrichment in DQB1
alleles encoding for an amino acid different
from Asp in position 57 (NA) and DQA1 alle-
les encoding for Arg in position 52 was
observed in diabetic subjects and first-degree
relatives as compared to controls. The geno-
type and allele frequencies of these polymor-
phisms in type 1 diabetic patients and first-
degree relatives differed significantly from
those of controls (p< 0.001 and 0.05 respec-
tively). CTLA-49 Ala alleles frequencies were
75.8% in type 1 diabetic patients and 68.1% in
first-degree relatives in comparison to 35.7% in
control subjects. The Ala/Ala genotype con-
ferred a relative risk of 18.8 (p < 0.001).
____________________
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fers an increased risk of type 1 diabetes, inde-
pendent of age and HLA-DQ genetic markers.
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INTRODUCTION
Type 1 diabetes, is a chronic disease charac-
terized by the autoimmune destruction of pan-
creatic β-cells resulting in complete insulin defi-
ciency [1]. The disease is quite heterogeneous in
its clinical expression [2]. A large body of evi-
dence indicates that inherited genetic factors
influence both susceptibility and resistance to
the disease. There is significant familial cluster-
ing with an average prevalence of 6% in sib-
lings as compared to 0.3% in a French
Caucasian population. The major susceptibility
locus lies within the HLA region on the short
arm of chromosome 6 [3], and provides up to
40-50% of the inheritable risk [4]. An associa-
tion between HLA class I alleles and type 1 dia-
betes was first described in the early 1970s [5,
6]. Subsequently, a closer association was
demonstrated between HLA-DR alleles and
type 1 diabetes [7] and DR3 and DR4 were
shown to be the major alleles associated with
this disease. More recent observations indicat-
ed that the genes in the HLA-DQ region were
even more closely associated with type 1 dia-
betes than the DR genes [8, 9, 10]. Several stud-
ies confirmed the association of DQB1 genes
with type 1 diabetes and demonstrated that
DQB1*02/0302 combination was the genotype
most closely associated with the disease. 
Whole-genome searches have identified at
least 15 additional chromosomal regions with
putative linkage to type 1 diabetes [11]. So far
only a minority of these candidate regions have
been confirmed as true susceptibility loci in
independent linkage and/or association studies.
Recently, linkage to and/or association with
type 1 diabetes of an A-to-G transition poly-
morphism at position 49 in the first exon of the
CTLA-4-gene (cytotoxic T lymphocyte associ-
ated antigen-4) on chromosome 2q33 (desig-
nated IDDM12) have been shown in data sets
from several countries [12]. This chromosomal
region contains the CTLA4 and CD28 genes
encoding for two molecules intimately involved
in the regulation of T-cell activation and prolif-
eration. Differential regulation of these mole-
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TABLE 1  Primers and restriction enzymes used for PCR-RFLP methods for HLA-DQB1, HLA-DQA1 and CTLA-4.
Primers restriction Location Target (bp) Expect
enzymes                                                           bands (bp)
5’-GATTTCGTGTACCAGTTTAAG-3’ Acy I HLA-DQB1 241, 137, 104, 70
5’-CCACCTCGTAGTTGTGTCTGC-3’ Hae III exon 2 241 241, 150, 127, 95
Hha I 189, 141, 112, 90
Hpa II 241, 198, 126, 115
5’-GGTGTAAACTTGTACCAG-3’ Dde I HLA-DQA1 225, 127, 118, 113 
5’-GGTAGCAGCGGTAGAGTTG-3’ Fok I exon 2        225  225, 187
Rsa I 225, 186, 183   
5’-GCTCTACTTCCTGAAGACCT-3’ Bbv-I CTLA-4 162  162, 88, 74
5’-AGTCTCACTCACCTTTGCAG-3’ exon 1   cules could easily affect T-cell function and
hence the regulation of the immune response.
Therefore, CTLA-4 gene is a strong candidate
gene for autoimmune diseases including type 1
diabetes. The present study aims to examine
the presence of genetic markers in a group of
first degree relatives recruited during the same
period as their diabetic probands.
RESEARCH DESIGN AND METHODS
PATIENT AND CONTROL SUBJECTS
Seventy-two (29 males, 43 females) healthy
first-degree relatives of type 1 diabetic patients
(n = 62) from 25 families participating in the
prospective based family study conducted in
the province of Alsace (France) were analysed
to investigate the role of genetic and environ-
mental factors in the development of type 1
diabetes. Out of the diabetic patients, 34 were
males and 11 had long-term type 1 diabetes of
over 30 years without complications. Type 1
diabetes was diagnosed according to the WHO
criteria [13]. The mean age at diabetes onset
was 13.3 years (range 5-38), and the mean
duration of the disease was 32.2 years (range 1-
37). Their first-degree relatives aged below 45
years were invited to take part. Informed con-
sent was obtained from the subjects. The local
ethical committee approved the study design.
Out of the first-degree relatives, 23 were sib-
lings (age 20 ± 14), 34 were offsprings (age 19
± 12), and 15 were parents (age 37 ± 6). Five
(offspring) were GAD antibodies positive and 7
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TABLE 2  Prevalence of genetic markers in type 1 diabetic patients, first-degree relatives and control subjects.
Genetic Control subjects   Type 1 diabetic First-degree   
marker (n = 84) patients (n = 62) relatives (n = 72) RR              
HLA-DQB1
NA 02 15 (8.9) 52 (41.9)*** 34 (23.6)***  7.5
NA 0302 21 (12.5) 38 (30.6)*** 21 (14.6)* 3.1
Others NA 12 (7.1)        22 (17.7)§ 33 (22.9) *** 2.8
A 0301 45 (26.8) 7 (5.6)*** 27 (18.8)* 0.2
A 0602 36 (21.4) 0 (0) 19 (13.2) ** -
Others A 39 (23.2) 5 (8.1)*** 10 (6.9) *** 0.1            
NA/NA 6 (7.1) 47 (75.8)*** 20 (27.8) *** 40.7
NA/A 48 (57.1) 15 (24.2)*** 43 (59.7) ** 0.2
A/A 30 (35.7) 0 (0) 9 (12.5) *** -
HLA-DQA1
Arg 0301 24 (14.3) 48 (38.7)*** 38 (26.4) ** 3.7
Arg 0501 36 (21.4) 46 (37.1)§ 52 (36.1) ** 2.2
Non-Arg 01 68 (40.5) 19 (15.3)*** 42 (29.2) ** 0.3
Non-Arg 0201 30 (17.9) 4 (3.2)*** 8 (5.5) *** 0.2
Others 10 (5.9) 7 (5.6) 4 (2.8) * 0.9
Arg/Arg 23 (27.4) 39 (62.9)*** 25 (34.7) * 4.5
Arg/Non-Arg 12 (14.3) 20 (32.3)** 36 (50.0) *** 2.9
Non-Arg/Non-Arg   49 (58.4) 3 (4.8)*** 11 (15.3) *** 0.04
CTLA-4
Thr 08 (64.3) 30 (24.2)*** 46 (31.9) *** 0.2
Ala 60 (35.7) 94 (75.8)*** 98 (68.1) *** 5.6
Thr/Thr 43 (51.2) 3 (4.8)*** 13 (18.1) *** 0.05
Thr/Ala 27 (32.1) 10 (16.1)** 25 (34.7) * 0.4
Ala/Ala 14 (16.7) 49 (79.0)*** 34 (47.2) *** 18.8
Data are n (%). *p > 0.05; **p< 0.05; §p < 0.01; ***p< 0.001 compared with control subjects.(3 sibling and 4 offspring) were IA-2 antibodies
positive. The group of control subjects were 84
randomly selected among normal blood donors
matched for age, gender and geographically, all
without known personal or familial history of
diabetes or other autoimmune diseases.
PCR-RFLP
The genomic DNA was subjected to PCR to
amplify the polymorphic regions in exon 2 of
the HLA-DQB1 gene (241 bp), DQA1 gene
(225 bp) and exon 1 of the CTLA-4 gene (162
bp) as follows: 200 ng of genomic DNA was
mixed with 20 µg of both upstream and down-
stream primers (Table 1), 10 mM dNTP, and
2.5 U of Taq polymerase in 50 µl of reaction
mixture containing PCR buffer (10 mM Tris,
pH = 8.4, 50 mM KCL, and 1.5 mM MgCl2).
Denaturation, annealing, and extension reac-
tions were performed at 95°C for 1 min, 55°C
for 2 min, and 72°C for 1 min respectively, and
the amplification was continued for 29 cycles
in a DNA Thermal Cycler (Mini Cycler, MJ
Research, CA, USA). Ten of the amplified PCR
products thus obtained were digested in 50 µl
with 2.5 U of the restriction enzymes (Table 1).
The fragments were analysed by PAGE.
STATISTICAL ANALYSIS
Differences in the prevalence of alleles or
genotypes between diabetic, first-degree rela-
tives and nondiabetic subjects were examined
using a χ2 test with Yates’ correction when
appropriate (one expected number < 5).
Statistical significance was defined as p < 0.05.
The relative risk (RR) conferred by a given
genetic marker was expressed as an odds ratio.
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TABLE 3  Prevalence of genetic markers according to age at clinical onset of type 1 diabetes
Age at clinical onset (years)
—————————————————————
Genetic marker           Controls 0-9  10-19 20-39
(n = 84)           (n = 14) (n = 19) (n = 29) p
HLA-DQB1
*02 15 (8.9)           16 (57.1)          18 (47.4)           18 (31.0) <  0.05
*0302 21 (12.5)         11 (39.3)          14 (36.8)          13 (22.4) < 0.05
HLA-DQA1
*0301 45 (26.8)        15 (53.6)           18 (47.4)            15 (25.9)        = 0.02
*0501 36 (21.4)        13 (46.4)           16 (42.1)            17 (29.3) ns
CTLA-4
Thr 108 (64.3)       7 (25.0) 12 (31.6) 11 (18.9) ns
Ala 60 (35.7)         21 (75.0)         26 (94.7)            47 (56.9) ns
Thr/Thr 43 (51.2)          1 (7.1) 2 (10.5) 0 (0) ns
Thr/Ala 27 (32.1)          2 (14.3)           5 (26.3) 3 (10.3) ns
Ala/Ala 14 (16.7)         11 (78.6)         12 (63.2)          26 (89.7) ns
Data are n (%), ns = not significantRESULTS
HLA-DQ ALLELE AND GENOTYPE DISTRIBUTION
The analysis of PCR-RFLP amplified DNA
from 62 type 1 diabetic patients, 72 first-degree
relatives and 84 controls matched for age and
sex revealed several DQB1 and DQA1 alleles
(Table 2). Comparing controls and diabetic
patients, a significant differences appeared
between diabetic patients and healthy control
subjects (Table 2). Indeed there is an increase in
Non-Asp57 (NA) allele from 28.6% in controls
to 90.3% in diabetics (p < 0.001 ; χ2 = 109 ;
OR = 23.3). In contrast, Asp 57 (A) allele
showed a decrease from 71.4% in controls to
9.7% in diabetic patients (p < 0.001 : χ2 = 110
; OR = 0.04). Moreover, the NA/A ratio was
reversed between controls (0.4) and diabetics
(9.2). Finally, an intermediate pattern was
observed for these alleles in the first degree rel-
atives (Table 2). Out of the 72 first-degree rela-
tives, 27.8% (20/72) were homozygous
NA/NA, 59.7% (43/72) were heterozygous
NA/A, and 12.5% (9/72) were homozygous
A/A. In controls, the frequency was 7.1% for
NA/NA, 57.1% for NA/A and 35.7% for A/A.
The HLA-DQB1*02 (NA) and DQB1*0302
(NA) were significantly increased in type 1 dia-
betic patients (χ2 = 43; p<10-3) as compared to
control subjects. The HLA-DQB1*02 allele
was also significantly increased in first-degree
relatives (χ2 = 12.6; p < 10-3). The relative risk
conferred by the HLA-DQB1*0302 allele was
less determinant than DQB1*02 (RR = 3.1 and
7.5 respectively). Moreover, the DQA1*0301
(Arg52) and DQA1*0501 (Arg52) alleles were
found highly increased in type 1 diabetics and
first-degree relatives (Table 2). Conversely, the
frequencies of HLA-DQB1*0602 (Asp57),
DQA1*01 (Non-Arg52) and DQA1*0201
(Non-Arg52) alleles were decreased among
patients and first-degree relatives. 
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TABLE 4  Interaction between CTLA-4 polymorphism and HLA-DQ 
CTLA-4 alleles CTLA-4 genotypes
——————————— —————————————————————
n Thr Ala Thr/Thr    Thr/Ala     Ala/Ala
Control subjects 84        108 (64.3)       60 (35.7)         43 (51.2)      27 (32.1)  14 (16.7)
Type 1 diabetic
Patients 62 30 (24.2)        94 (75.8)            3 (4.9) 10 (16.1)      49 (79.0)
HLA-DQB1
*02 (+) 26 12 (23.1)        40 (76.9) 2 (7.7) 4 (15.4)       20 (76.9)
*02       (-) 36 18 (25.0) 54 (75.0) 1(2.8) 6 (16.7) 29 (80.6)
p ns ns - ns ns
*0302    (+) 19 8 (21.1) 30 (78.9) 0 (0) 3 (15.8) 16 (84.2)
*0302    (-) 43 22 (25.6) 64 (74.4) 3 (6.9)       7 (16.3) 33 (76.7)
p ns ns - ns ns
HLA-DQA1
*0301   (+)  24 10 (20.8) 38 (79.2) 1 (4.2)       4 (16.7) 19 (79.2)
*0301   (-) 38 20 (26.3) 56 (73.7) 2 (5.3)       6 (15.8) 30 (78.9)
p ns ns - ns ns
*0501    (+) 23 12 (26.1) 34 (73.9) 0 (0) 5 (21.7) 18 (78.3)
*0501    (-) 39 18 (23.1) 60 (76.9) 3 (7.9)       5 (12.8) 31 (79.5)
p ns ns - ns ns
Data are n (%)CTLA-4 49 (A/G) POLYMORPHISM
The genotype and gene frequencies of
CTLA-4 polymorphism in type 1 diabetes and
first-degree relatives differed significantly (p <
10-3) from those of control subjects (Table 2).
Frequencies in the base transition in codon 49
to encode for Thr or Ala were 24.2% (30/124)
and 75.8% (94/124) respectively in patients
with type 1 diabetes; 31.9% (46/144) and
68.1% (98/144) in first-degree relatives, where-
as 64.3% (108/168) and 35.7% (60/168) were
found in controls (χ2 = 43.5; p < 10-3 and χ2 =
33.5; p < 10-3 respectively). The frequency of
the Ala/Ala genotype was increased in diabetics
and first-degree relatives (79% and 47.2%
respectively versus 16.7% in control subjects).
The relative risk of type 1 diabetes conferred by
the Ala/Ala genotype was rather high and mod-
erate with the Ala allele (RR = 18.8; 10-3 and
RR = 5.6; 10-3 respectively).
PREVALENCE OF GENETIC MARKERS ACCORDING
TO AGE AT CLINICAL ONSET OF TYPE 1 DIABETES
The 62 patients were stratified according to
age in three categories: 0-9 (n = 14), 10-19 (n =
19), and 20-39 (n = 29) years (Table 3). The
fraction of patients carrying the Ala allele or
Ala/Ala genotype did not differ significantly
among the various groups. Consequently, the
presence for the Thr allele or Thr/Thr and
Thr/Ala genotypes was also age-independent as
previously showed [25]. In contrast, within the
same group, the prevalence of HLA-
DQB1*0302 and DQA1*0301 alleles declined
with age at onset.
CTLA-4 49 (A/G) POLYMORPHISM AND
HLA-DQ-LINKED RISK
Because the difference in HLA-DQ locus in
diabetic subjects might affect the distribution of
the CTLA-4 alleles or genotypes to susceptibil-
ity to diabetes, the patients were sub-divided
according to HLA-DQ and comparison was
made between the diabetic patients with or
without HLA-DQB1*02, DQB1*0302,
DQA1*0301 or DQA1*0501. However, the
frequency of CTLA-4 alleles or genotypes was
independent of the susceptible HLA-DQ status
(Table 4).
DISCUSSION
Susceptibility to type 1 diabetes has been
previously shown to be highly correlated with
the absence of an Asp57 on the DQβ chain
[14], and the presence of an Arg52 on the DQα
chain [15]. Nevertheless, the absence or pres-
ence of these residues in the DQ sequences of
type 1 diabetic patients cannot entirely deter-
mine the susceptibility or the resistance to the
disease [14, 16]. In this study we confirmed the
importance of DQβAsp57 and DQαArg52
codons in that susceptibility. The distribution
of HLA-DQB1 and DQA1 alleles among dia-
betic patients and healthy controls was compa-
rable to that in previous reports and closely
matched with the reported frequencies in
Caucasian individuals [17, 18, 19]. The fre-
quency of high-risk alleles DQB1*02,
DQB1*0302 and DQA1*0301 increased in
type 1 diabetic patients. We also confirmed the
high frequency of HLA-DQ risk alleles in first-
degree relatives [20, 21, 22]. 
Age-dependent HLA heterogeneity has been
observed in Caucasian type 1 diabetic patients
indicating that high risk HLA genotypes or
alleles occurred at a higher frequency among
the younger age onset groups [23, 24]. In this
study, diabetic patients were stratified accord-
ing to age of onset in three categories: 0-9, 10-
19, and 20-39 years. Our data analysis of
HLA-DQB1 alleles confirm this age-dependent
susceptibility. The HLA-DQB1 alleles
(DQB1*02 and DQB1*0302) were present in
53.4% of adults patients (20-39 yrs) and
96.4% in type 1 diabetics children (0-9 yrs) as
compared to only 21.4% in controls (p<
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there were also difference between the adult
and younger patients. Previous studies in other
countries already showed this HLA-age-
dependent risk [25, 26]. Caillat-Zucman et al.
found a decreased frequency of DR3 and DR4
haplotypes and DR3/DR4 heterozygosity
amongst patients who had developed diabetes
after the age of 15 [17].
Moreover, the probable involvement of
CTLA-4 49 (Thr/Ala) polymorphism in type 1
diabetes was analysed in this study. Our results
based on PCR-RFLP of exon 1 in 218 individ-
uals, including 62 type 1 diabetic patients and
72 first-degree relatives, proved the involve-
ment of a CTLA-4 49 (Thr/Ala) polymorphism
in type 1 diabetes susceptibility, consistent with
the data sets from several countries including
Belgium, Germany and Japan [12, 27, 28, 29],
but not in others [30]. Thus, there seems to be
an ethnic difference in the role of the CTLA-4
49 (Thr/Ala) polymorphism. CTLA-4 is a mem-
ber of the immunoglobulin superfamily, more
specifically of the subgroup of molecules with a
single V (variable) domain [31] and detectable
on T cells only after antigen presentation.
CTLA-4 deficient mice have shown extensive T
cell proliferation, B cell activation, and a
marked rise in serum immunoglobulin concen-
trations [32]. Signalling through CTLA-4 may
down-regulate proliferative responses by
inhibiting the production of IL-2, or the
expression of IL-2 receptors [33, 34]. Therefore
CTLA-4 plays an important inhibitory role in
regulating lymphocyte expansion and might be
responsible for the disruption of the delicate
balance between TH1 and TH2 lymphocytes
by preventing down-regulation of activated self
reactive T cells [35].
In contrast to the HLA-DQB1 alleles, the
risk conferred by CTLA-4 Ala allele did not
decrease with age at clinical onset, confirming
the results of Van der Auwera [25]. HLA locus
may have strong confounding effects and
obscure the role of CTLA-4 49 (Thr/Ala) poly-
morphism in a case-control study [36]. Thus,
we further analysed this polymorphism in con-
junction with DQ locus and failed to detect any
difference in its effect according to HLA-DQ
status like Van der Auwera [25]. It was found
in this study that association of CTLA-4 with
diabetes was not affected by HLA-DQ suscep-
tibility alleles. This last result is in contradic-
tion with Badenloop’s data, which showed that
the CTLA-4 predisposing variant increased dia-
betes risk in synergy with HLA-DR3 but not
with HLA-DR4 in a German population [37].
The discrepancy between ours and the result of
Badenloop et al [37] might be due to the size
and degree of homogeneity of families. The size
of ours families was much smaller than that of
Badenhoop’s German families (25 vs130).
The analysis of an A-G transition in the first
exon of the CTLA-4 gene, coding for a Thr/Ala
substitution in the leader peptide, showed a
preferential transmission to the affected sib-
lings [12]. A similar relationship was also
reported in Japanese patients with type 1 dia-
betes and with autoimmune thyroid disease
[28, 38]. Although, such a relationship was not
observed in families from Sardinia, U.K, U.S.A,
or Denmark [39, 40]. 
In conclusion, this study demonstrated that
CTLA-4 49 (Thr/Ala) polymorphism was asso-
ciated with type 1 diabetes and that the CTLA-
4 49 Ala allele conferred an increased risk to
type 1 diabetes independently of age and HLA-
DQ genetic markers.
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